Vendor: Marketplace supplier
Product metadata will be available once the catalog entry is complete.
Formulations: - Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule Oral > Liquid: 10%; 20% Indications: - Acute or subacute hepatic failure - Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate) Indications: - Harmful effects of drugs, medicaments or biological substances, not elsewhere classified - Other specified sickle cell disorders or other haemoglobinopathies - Thalassaemias Source: EML workbook import
Formulations: - Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule Indications: - Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base) Indications: - Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule Indications: - Acquired methaemoglobinaemia Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride) Indications: - Unintentional exposure to or harmful effects of opioids or related analgesics Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.
